Menu
Recruiting NCT07566832

Velocity-Based Resistance Training Effects on Inflammation in Older Adults

No phase Interventional Aging Inflammatory Response

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Resistance exercise.
Who it may be relevant to
Registry conditions: Aging, Inflammatory Response. Basic parameters: 60 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults

Overview

This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults. Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group. Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase. The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.

Interventions

  • Other Resistance exercise
    The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.

Primary outcome measures

  • Changes in IL-6 concentration [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in soluble IL-6 receptor concentration [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in soluble gp130 concentration [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in IL-10 concentration [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in IL-1RA concentration [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in TNF-α concentration [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
Secondary outcome measures (12)
  • Borgs Ratings of Perceived Exertion (RPE) [Time frame: 1-hour during each exercise intervention]
  • Handgrip strength [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Knee extension strength [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • 30-second chair-stand test [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Single-leg balance test [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Timed up and go test [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs) [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in gp130 (CD130) protein expression in PBMCs [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in STAT3 protein expression in PBMCs [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in phosphorylated STAT3 protein expression in PBMCs [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]
  • Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs [Time frame: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining]

Eligibility criteria

Inclusion criteria

  • Aged 60-75 years or older
  • No regular resistance training habit (defined as ≥2 sessions per week) in the past year
  • No musculoskeletal injuries within the past six months

Exclusion criteria

  • Obesity (BMI > 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
  • Regular use of anti-inflammatory medications (e.g., NSAIDs).
  • Smoking or alcohol abuse
  • Inability to safely perform the prescribed resistance exercise movements
  • Unable to fully comprehend the study information and instructions.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Open label
Primary purpose
Treatment

Study locations

Taiwan · 1 center
  • National Taiwan Normal University — Taipei

Identifiers

NCT: NCT07566832 · ECKIRB1140803

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗